initi outperform pt
wan na play cyclic okay say hello littl gc
unabashedli bullish share agil time
buy transform led ceo mcmullen argu
rel price-to-earnings expans growth improv multipl expans
portion trade certainli play still see superior
growth profil given outsiz exposur cyclic end market
averag omx potenti enter see upsid estim
continu strength potenti us would also result
better model omx core drive outsiz increment
omx also like see continu boost optim exist
infrastructur well effort drive continu improv across
entir suppli chain anoth key potenti medium-term driver ep
upsid tax reform agil substanti off-shore cash could
brought back lower debt level also aggress buy share
fear pharma slowdown overplay new product roll-out
furthermor see limit downsid risk slowdown pharma
europ tough comp like follow moder
demand dynam within forecast new product momentum
pharma vertic also robust allow averag
share captur even case pronounc capital-expenditure slowdown
unlik view all-in see strong mid-to-high teen ep growth
go forward abl sustain premium
 in-lin histor level despit improv growth given
dynam see risk reward favor thu initi share
o/p rate
thing watch trajectori global pmi path oil price
 capital-expenditure commentari repatri use ou cash
debat recent slowdown biopharma growth
tempor like surpris upsid
right level peak margin
valuat price target base dcf methodolog
contempl wacc termin ebitda multipl
equat perpetu growth rate pt
translat ebitda vs average
price-to-earnings basi translat vs average
downsid risk potenti downward shift volatil
oil price subdu demand relat analyt instrument
increas scrutini drug price place downward pressur
 budget limit capital-expenditure demand within complex slowdown
china relat demand given shift govern polici materi
depress key geograph driver core growth overinvest
preoccup strategi divert manag attent away
core dgg lead mix execut manag use
repatri process pay debt leav balanc sheet woefulli
underutil limit return core revenu
unwilling flex cost structur yield margin compress evok
imag agil pre mike
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
initi outperform pt
wan na play cyclic okay say hello littl gc
last page report import disclosur regard stock report
tabl content
debat recent slowdown biopharma growth tempor
debat like surpris upsid
debat right level peak margin
point differenti vs st
iv valuat risk elev price-to-earnings reflect beat
 conclus initi o/p cyclic bias growth
high-end analyt provid midst transform
acg effort help balanc product portfolio
divers analyt technolog provid strength
life scienc appli market well emerg
thesi superior ep growth given cyclic bia core
peer omx consist capit return buoy nt
tax reform repatri support elev valuat
rate valuat pt outperform pt
ebitda vs average
price-to-earnings vs average
tighten biopharma capital-expenditure budget
outsiz exposur china pharma
ceo mcmullen led transform effort
previous presid
jacob thaysen presid diagnost genom
join dako acquisit
suppli chain yr
debat recent slowdown biopharma growth tempor
agil saw greater biopharma deceler peer
mani concern durat current capital-expenditure cycl
howev reason weak appear tempor
new product provid momentum
tough comp face comp
manag anticip deceler
lumpi revenu due batch-bas orders/project
infin ii lc launch end
later inning yr lc upgrad cycl
ultivo triple-quad lc/m launch end
cycl infanc contribut next leg growth
infin wind
europ longer sale convers cycl couldnt convert
high-end mass spec order sale time
lc replac cycl small molecul deceler
expect given tail end infin ii cycl
earli inning like contribut overal
growth next yr
new product replac workhors instrument field
year
management guidanc growth appear attain given new product momentum
debat like surpris upsid
 o/p end market last
agil also o/p rest tool industri
major recoveri chemic side
feel stable/improv
 side troubl
year
increas capital-expenditure
role recoveri
start see
improv
refin side
 revenu subseg
 growth like major driver ep upsid
debat right level peak margin
manag done tremend job drive omx
plenti omx left despit close gap peer
gain like continu come dgg
major omx
came dgg
model summari point differenti vs street
swing factor pharma use repatri proce bia capit alloc
point differenti
core still
remain key peer
ep st w/
capit alloc
repatri
forecast like conserv core w/ repatri usag crucial
million except per share data fy end decemb scienc appli market organ genom organ cross organ measurementtot organ gp less total scienc appli market genom cross op less ep share inc net inc price-to-earnings prem disc januari
valuat undeni elev consist rel basi
agil longer inexpens superior growth trajectori support rel premium
risk point favor risk reward profil macro factor point posit revis vs capital-expenditure moder
potenti downward shift volatil oil price subdu demand relat analyt instrument
increas scrutini drug price place downward pressur budget limit capital-expenditure demand within complex
slowdown china relat demand given shift govern polici materi depress key geograph driver core growth
overinvest preoccup strategi divert manag attent away core dgg lead mix execut
manag use repatri process pay debt leav balanc sheet woefulli underutil limit return
slowdown core revenu unwilling flex cost structur yield margin compress evok imag agil pre mike
dcf valuat yield price
dcf deriv pt impli termin growth rate impli ebitda multipl
assumpt underli dcf valuat methodolog
year ebita margin assumpt
termin ebitda multipl
tax rate
wacc base beta risk free rate cost debt
assumpt impli termin growth rate
discount ebitda termin free flow enterpris total valu valu per perpetu growth valu enterpris enterpris valu januari
conclus initi outperform pt upsid
transform middl inning allow superior ep growth w/ upsid kicker repatri
unabashedli bullish share agil time buy
transform led ceo mcmullen argu rel price-to-earnings expans growth improv
multipl expans portion trade certainli play still see superior
growth profil given outsiz exposur cyclic end market averag omx potenti
enter see upsid estim continu strength potenti us
would also result better model omx core drive outsiz increment
omx also like see continu boost optim exist infrastructur well
effort drive continu improv across entir suppli chain
anoth key potenti medium-term driver ep upsid tax reform agil substanti
off-shore cash could brought back lower debt level also aggress buy share
furthermor see limit downsid risk slowdown pharma europ tough
comp like follow moder demand dynam within forecast
new product momentum pharma vertic also robust allow averag
share captur even case pronounc capital-expenditure slowdown unlik view
all-in see strong mid-to-high teen ep growth go forward abl
sustain premium in-lin histor level despit improv growth
given dynam see risk reward favor thu initi share o/p rate
thing watch global pmi oil price capital-expenditure commentari repatri
pleas feel free reach question follow-up
medic suppli devic
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin januari et
analyst ross muken vijay kumar luke sergott primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research
